TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9657323
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae immunotherapy
Study: 30427093
Drug: Oral nanocurcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nanocurcumin (120 mg/day)
Study: 16704555
Drug: Glipizide 2.5
Normalized name: glipizide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 2.5 mg once daily for 6 months
Study: 30793431
Drug: Elobixibat 10
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 10 mg/d
Study: 30793431
Drug: Elobixibat 15
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 15 mg/d
Study: 30793431
Drug: Elobixibat (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elobixibat (varied doses 5-15 mg/d)
Study: 28270028
Drug: Health Education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Education Session (HES) administered to the Intervention Group (IG)
Study: 21846617
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily in addition to standard treatment
Study: 2566942
Drug: Glucose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (100 g p.o. 45 min before GHRH)
Study: 50159
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (THC) 20 mg
Study: 50159
Drug: Delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (THC) 10 mg
Study: 29934985
Drug: Medial knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial knee pain (MP) induced by hypertonic saline (0.5 mL) injection
Study: 29934985
Drug: Lateral knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral knee pain (LP) induced by hypertonic saline injection
Study: 28669654
Drug: 3% H2
Normalized name: Hydrogen Peroxide 3%
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% H2 gas inhalation (1 hour twice a day for 2 weeks)
Study: 28669654
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous medications (for the initial 7 days)
Study: 9638964
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg
Study: 23197250
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg plus Ezetimibe 10 mg
Study: 21645439
Drug: UDCA-monotherapy
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA-monotherapy
Study: 18075220
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of plant sterol in 15 g dressing for 4 weeks
Study: 18075220
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day of plant sterol in 15 g dressing for 4 weeks
Study: 18075220
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day of plant sterol in 15 g dressing for 4 weeks
Study: 18075220
Drug: 2400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/day of plant sterol in 45 g dressing for 4 weeks
Study: 10734658
Drug: No ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ATRA administration
Study: 9182474
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg per week, preceded by a loading dose of 250 mg/d for 3 days)
Study: 9182474
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg per day)
Study: 9182474
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for both drugs
Study: 2957520
Drug: Functional restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional restoration treatment program
Study: 2957520
Drug: Small treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small treatment dropout group
Study: 22961573
Drug: RM-131 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM-131 (100 μg s.c.)
Study: 19544672
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate (CAL, 1.2 to 1.8 g/day)
Study: 8236070
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (500 micrograms twice a day)
Study: 3912618
Drug: T-CAF (Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-CAF (Chemotherapy plus Tamoxifen)
Study: 3912618
Drug: CAF (Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (Chemotherapy only)
Study: 26253006
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CD34+ stem cells (10 to 15 × 10^6 cells/kg)
Study: 26253006
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CD34+ stem cells (4 to 6 × 10^6 cells/kg)
Study: 15726101
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid therapy (> or =25 mg prednisolone or > or =4 mg dexamethasone daily for > or =4 weeks)
Study: 10588995
Drug: Zafirlukast 80
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 80 mg twice daily
Study: 656284
Drug: Intra-articular prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular prednisolone acetate (50 mg and 100 mg)
Study: 28705153
Drug: TDF/FTC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC tablet once daily (Perfect adherence)
Study: 24683783
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam spray
Study: 21076361
Drug: Low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methadone (0.1 mg/kg/dose)
Study: 21076361
Drug: High-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methadone (based on weight and fentanyl infusion rate)
Study: 19801052
Drug: Once-daily physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily physiotherapy (Control)
Study: 11264335
Drug: Moclobemide plus
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide plus interpersonal therapy (IPT)
Study: 9272198
Drug: Pirlindole (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirlindole (150-300 mg daily)
Study: 7593728
Drug: Moclobemide (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300-600 mg daily)
Study: 8100105
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) 0.5 mg subcutaneously
Study: 3555057
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for five days
Study: 1538580
Drug: Taurine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (3 g/day)
Study: 20025642
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin for 21 days
Study: 12633920
Drug: Corticosteroid (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (prednisolone 2 mg/kg per day)
Study: 12633920
Drug: Antihistamine (chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (chlorpheniramine maleate 0.35 mg/kg per day)
Study: 30714880
Drug: Standard buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard buprenorphine treatment
Study: 26355615
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2% and benzoyl peroxide 3.75% aqueous gel
Study: 31713863
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (limited duration anticoagulation)
Study: 28216012
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (received HMME-PDT treatment in the second session)
Study: 22015710
Drug: DE plus
Normalized name: Nicotinamide Plus Zinc Plus Folic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE plus metformin
Study: 19808138
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of levofloxacin 500 mg
Study: 16639920
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA): 3 mg dissolved in 250 mg of physiological saline given every 12 hours for a maximum of 20 days.
Study: 16639920
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of rt-PA used for treatment of myocardial infarction (not specified in the abstract).
Study: 16277666
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs
Study: 2216299
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) 45 mg/m2 orally on 3 consecutive days every 28 days
Study: 2216299
Drug: Doxorubicin (ADRIA)
Normalized name: doxorubicin Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (ADRIA) 75 (60) mg/m2 intravenously every 21 days
Study: 358756
Drug: Diazepam (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (intramuscular injections)
Study: 358756
Drug: Barbital (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbital (oral route)
Study: 26019183
Drug: Low-dose THC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose THC (2.9%) with alcohol
Study: 26019183
Drug: High-dose THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose THC (6.7%) with alcohol
Study: 23530566
Drug: Thai traditional
Normalized name: Thai galangal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thai traditional massage (2-hour session, twice a week for 4 weeks)
Study: 19159408
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily) for 10 days
Study: 10441849
Drug: haemocorrecting drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: haemocorrecting drugs (rheopolyglucin, euphyllin, aspirin, curantyl, trental)
Study: 10441849
Drug: vasoactive and
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vasoactive and metabolic drugs (cavinton, complamin, actovegin)
Study: 7790793
Drug: High‐dose, motorized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose, motorized, continuous traction (35%-50% of total body weight)
Study: 7790793
Drug: Sham or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham or low‐dose traction (0-20% of body weight)
Study: 7790793
Drug: High‐dose, motorized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose, motorized, continuous traction
Study: 7790793
Drug: Sham or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham or low‐dose traction
Study: 23973639
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg/day (Group B)
Study: 20558925
Drug: Culture-guided triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-guided triple therapy
Study: 15888211
Drug: Naloxone (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.04 mg/kg, I.V.)
Study: 1971027
Drug: Terazosin (2-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2-40 mg, once daily)
Study: 7060823
Drug: Sodium meclofenamate
Normalized name: Meclofenamate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium meclofenamate (300 mg daily)
Study: 17453399
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg daily)
Study: 31266654
Drug: Dapagliflozin 5-mg/saxagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP
Study: 31266654
Drug: Dapagliflozin 10-mg/saxagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP
Study: 24584741
Drug: 20% intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% intralipid infusion
Study: 7531852
Drug: Hydromorphone (1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1‐6 mg/70 kg)
Study: 26948856
Drug: 16 mg/day
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/day BUP (BUP16)
Study: 25110280
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg (Treatment C)
Study: 19675104
Drug: P +
Normalized name: Stress Formula B-Comp + Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: P + 60 mg/d iron (Fe)
Study: 15240537
Drug: Conventional-dose anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose anthracycline-based chemotherapy
Study: 15240537
Drug: High-dose anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anthracycline-based plus alkylating chemotherapy
Study: 15240537
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (surgical or chemotherapy regimen and histological type)
Study: 9054819
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered within 2 hours of symptom onset
Study: 9054819
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered after 4 to 6 hours of symptom onset
Study: 9054819
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered after 1 hour of arrival at hospital
Study: 3322848
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac 75 mg
Study: 2427301
Drug: middle-molecular hydroxyethyl
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: middle-molecular hydroxyethyl starch solution
Study: 2427301
Drug: isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic sodium chloride solution
Study: 7564132
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (Doxium) 3 x 500 mg orally for 2 years
Study: 2201161
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium hyaluronate solution
Study: 2201161
Drug: 2% methylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% methylcellulose solution (placebo)
Study: 7299760
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg 3 days/week)
Study: 7299760
Drug: D-penicillamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (250 mg increments at 2-3 monthly intervals)
Study: 23807094
Drug: CRP concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP concentration ≥ 40 mg/L
Study: 21155632
Drug: MPH ER
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH ER (up to 1 mg/kg per day)
Study: 19951567
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin lispro low mix 25
Study: 19951567
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin mix 30/70
Study: 19951567
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro low mix 25
Study: 7679583
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg three times a day after a 6.25 mg test dose, n = 32)
Study: 30593463
Drug: Salbutamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (4 mg, three times a day)
Study: 28791362
Drug: COPD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD treatment group
Study: 26401255
Drug: HIV protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV protease inhibitors (HIV‐PIs) saquinavir and ritonavir (SQV+RIT)
Study: 23467813
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus vitamin B12 supplementation (2 mg of folic acid and 400 μg of vitamin B12 daily for 16 weeks)
Study: 17079524
Drug: Counterstrain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counterstrain treatment
Study: 9564119
Drug: Chlorpromazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25 mg/day) + Tropisetron (TRO) (5 mg/day)
Study: 9564119
Drug: Chlorpromazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25 mg/day) + Tropisetron (5 mg/day) + Dexamethasone (2 mg/day)
Study: 9564119
Drug: Tropisetron (TRO)
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (TRO) (5 mg/day)
Study: 2721537
Drug: Co-dergocrine 4
Normalized name: co-dergocrine mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-dergocrine 4 mg/day for 3 weeks
Study: 5483323
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate administered with tetracycline
Study: 5483323
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate administered with oxytetracycline
Study: 5483323
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate administered with methacycline
Study: 5483323
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate administered with doxycycline
Study: 5483323
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of iron taken simultaneously with tetracycline
Study: 25848072
Drug: Shock-wave (SW)
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock-wave (SW) therapy
Study: 19487995
Drug: Deep breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep breathing exercises along with usual treatment for pain
Study: 19487995
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment for pain (Control)
Study: 22748821
Drug: Glimepiride (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-4 mg)
Study: 8086025
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine
Study: 3353525
Drug: thoracic EA
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: thoracic EA with bupivacaine (0.5%) in combination with a light general anesthesia
Study: 21614414
Drug: cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol 100 mg
Study: 12718508
Drug: Ivermectin capsules
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin capsules
Study: 9928754
Drug: Verapamil SR/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR/trandolapril 120/0.5 mg o.d. (dose step 1)
Study: 9928754
Drug: Verapamil SR/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR/trandolapril 180/2 mg o.d. (dose step 3)
Study: 8601264
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs, sunscreens, topical and intra-lesional corticosteroids, antimalarials
Study: 8601264
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids or immunosuppressants
Study: 8601264
Drug: Antihypertensives, cholesterol-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensives, cholesterol-lowering drugs, hypoglycemic agents
Study: 7471064
Drug: Pseudoisocytidine (psi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoisocytidine (psi ICyd) administered via daily i.v. injection for 5 consecutive days
Study: 21083737
Drug: Ricinus communis
Normalized name: Ricinus communis oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ricinus communis solution (RC)
Study: 8641247
Drug: Blackcurrant-strawberry nectar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant-strawberry nectar (200 ml, twice daily for 4-5 weeks, vitamin C content approximately 70 mg/100 g)
Study: 1727913
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 every 21 days IV)
Study: 1727913
Drug: ICRF‐187 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRF‐187 1,000 mg/m2 IV
Study: 15673327
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 to 180 mg/day)
Study: 3280097
Drug: Intravenous urography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urography
Study: 7193307
Drug: Levodopa administered
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa administered rectally
Study: 29145211
Drug: S-1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 therapy
Study: 22143488
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment (adapted for prevention of depression)